investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Novel Point-of-Care Tool to Predict Response to Sorafenib in Hepateocellular Carcinoma
Ahmed Kaseb
4 Collaborator(s)
Funding source
University of Texas MD Anderson Cancer Center
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Ahmed Kaseb
University of Texas MD Anderson Cancer Center
Houston, United States
Yaojun Zhang
Sun Yat-sen University
Guangzhou, China
Yongyut Sirivatanausksorn
Mahidol University
Bangkok, Thailand
Do Young Kim
Yonsei University
Seoul, South Korea
Ashraf Omar
Cairo University
Giza, Egypt
Related projects
Jeffrey N Martin
Uganda-UCSF Consortium on Prevention and Early Detection of HIV-Associated Cancer - Uganda, Kenya, San Francisco
Liver and intrahepatic bile ducts
Pathology
Banchob Sripa
Pathogenesis, Carcinogenesis and Ecology of Opisthorchiasis in Thailand
Liver and intrahepatic bile ducts
Pathology
Richard T D'Aquila
Third Coast Center for AIDS Research
Liver and intrahepatic bile ducts
Pathology
Jean-Francois H Geschwind
See, Reach, Treat Tumor-Optimized Transarterial Chemoembolization DrugDelivery
Liver and intrahepatic bile ducts
Pathology
Marshall Hicks
Clinical Relevance of FGF19 Signaling in the Resistance to Image-guided Therapy in Hepatocellular Carcinoma
Liver and intrahepatic bile ducts
Pathology
Jian-Min Yuan
Prospective Studies of Cancer Etiology and Prevention in Shanghai and Singapore
Liver and intrahepatic bile ducts
Pathology
Jean-Francois H Geschwind
See, Reach, Treat Tumor-Optimized Transarterial Chemoembolization Drug Delivery
Liver and intrahepatic bile ducts
Pathology
Gregory D Kirk
HIV and Hepatocellular Carcinoma in Uganda: The H2U Consortium
Liver and intrahepatic bile ducts
Pathology
William G Nelson
Chronic exposure to aflatoxin and the risk of liver cancer, fatty liver disease, liver fibrosis, and diabetes
Liver and intrahepatic bile ducts
Pathology
